Physician profile
Greg S Steinbock
NPI 1972590057
$134,127.55
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $25K · 2021: $12K · 2022: $61K · 2023: $5,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,185 · Travel and Lodging: $1,511 · Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,185.00 |
| Travel and Lodging | $1,511.43 |
| Food and Beverage | $1,146.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Whip Mix Corporation | $71,661.95 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17,534.89 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $10,279.41 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Astellas Pharma US INC | $9,615.14 | 2019-2023 | Xtandi |
| Pfizer INC. | $7,983.80 | 2019-2023 | |
| Janssen Biotech, INC. | $6,816.06 | 2019-2023 | Erleada |
| Clovis Oncology, INC. | $2,332.02 | 2019-2020 | |
| Exelixis INC. | $1,980.00 | 2021 | |
| Dendreon Pharmaceuticals LLC | $1,727.55 | 2019-2023 | Provenge |
| Blue Earth Diagnostics | $619.90 | 2019-2022 | |
| Medtronic USA, INC. | $540.00 | 2019-2020 | |
| Medtronic, INC. | $499.36 | 2021-2022 | |
| Amgen INC. | $493.20 | 2019-2022 | |
| Abbvie INC. | $466.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $177.84 | 2019-2023 | Lynparza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $160.66 | 2022 | |
| Boston Scientific Corporation | $152.03 | 2019 | |
| Teleflex LLC | $133.44 | 2021 | |
| Urogen Pharma, INC. | $119.72 | 2022 | |
| Siemens Medical Solutions USA, INC. | $116.63 | 2021 | |
| Myovant Sciences INC. | $98.67 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $84.18 | 2023 | Orgovyx, Gemtesa |
| Foundation Medicine, INC. | $82.79 | 2020-2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Sun Pharmaceutical Industries INC. | $72.36 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $71.87 | 2019-2021 | |
| Axonics, INC. | $49.04 | 2023 | Axonics |
| Tolmar Pharmaceuticals, INC. | $45.98 | 2019 | |
| Ferring Pharmaceuticals INC. | $44.82 | 2019 | |
| Progenics Pharmaceuticals, INC. | $37.24 | 2022-2023 | Pylarify |
| E.R. Squibb & Sons, L.L.C. | $33.93 | 2022 | |
| Neotract INC. | $25.12 | 2019 | |
| Coloplast Corp | $20.46 | 2022 | |
| Eisai INC. | $19.00 | 2021 | |
| Accord Healthcare, INC. | $17.06 | 2023 | |
| Angiodynamics, INC. | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$779,583.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Steinbock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.